These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Psychometric attributes of the rating scale for gait evaluation in Parkinson's disease.
    Author: Serrano-Dueñas M, Calero B, Serrano S, Serrano M, Coronel P.
    Journal: Mov Disord; 2010 Oct 15; 25(13):2121-7. PubMed ID: 20721925.
    Abstract:
    BACKGROUND: The RSGE-PD-V2.0 is a specific measure for evaluation of gait impairment in PD. OBJECTIVE: To check the RSGE-PD-V2.0 metrics attributes. METHODS: In addition to demographic and historical data of PD, applied assessments were: Hoehn and Yahr staging (H&Y); impact in daily activities with Schwab and England scale (S&E); SCOPA Motor; mental status with Short portable mental status questionnaire (SPMSQ); quality of life with Parkinson's impact scale (PIMS), the Hamilton Depression Rating Scale-6 items (HDRS-6); and, the Clinical Impression of Severity Index-PD (CISI-PD). RESULTS: 151 PD patients were included (n = 102 (67.5%) were male). Most patients were in H&Y stage 3 (n = 78 (51.6%)). Mean of age and duration of disease was 68.4 and 7.6 years respectively. Mean values of L-Dopa doses was 652.6 mg/day. Mean values of SCOPA Motor were 29.1; SPMSQ: 1.8; HADS-6: 9.2; PIMS: 18.7;RSGE-PD-V2.0: 25.4; and, CISI-PD were 10.8. Full computable scores were 100%; Guttman's lambda, 0.954; and the item-total correlation, 0.408-0.830. Correlation coefficients (Spearman's rho) between RSGE-PD-V2.0 and H&Y, S&E, SCOPA Motor, PIMS and CISI-PD, were: 0.62; -0.75; 0.74; 0.46; and, 0.78 respectively. RSGE-PD-V2.0 scale significantly discriminated among PD severity levels (based on H&Y staging) Kruskal-Wallis (p < 0.000). CONCLUSIONS: Metric attributes of the RSGE-PD-V2.0 in this sample of study resulted in has sufficient and suitable satisfactory. We, therefore, believe that RSGE-PD-V2.0 is easy and a useful and recommendable specific tool for measuring gait disease in PD patients.
    [Abstract] [Full Text] [Related] [New Search]